2nd Part of the Avastin Story -Off Label abuse in the german Journal "Pharmarecht"
Written by the former president of BAS. That is why they do not generate any significant revenue in Germany. Bob Jahr’s strategy to enter the market alongside Avastin has failed. The only option would have been to take legal action against the off-label use of Avastin. However, Outlook rejected the approach proposed by a consulting firm. That firm had also predicted the disaster. Sales potential for Lytenava alone in Germany: 150 million per year.
Translated with DeepL.com (free version)
u/volleasy — 4 days ago